Modulation of vascular tone by activators and inhibitors of membrane potassium channels in isolated conductance and capacitance blood vessels with especial regard to levosimendan, an inodilator drug by HASH(0x7fe9905eff38)
MODULATION OF VASCULAR TONE BY ACTIVATORS 
AND INHIBITORS OF MEMBRANE POTASSIUM 
CHANNELS IN ISOLATED CONDUCTANCE AND 
CAPACITANCE BLOOD VESSELS WITH ESPECIAL 
REGARD TO LEVOSIMENDAN, AN INODILATOR DRUG 
Ph.D. Thesis 
József Höhn M.D. 
- 2 0 0 6 -

MODULATION OF VASCULAR TONE BY ACTIVATORS 
AND INHIBITORS OF MEMBRANE POTASSIUM 
CHANNELS IN ISOLATED CONDUCTANCE AND 
CAPACITANCE BLOOD VESSELS WITH ESPECIAL 
REGARD TO LEVOSIMENDAN, AN INODILATOR DRUG 
Ph.D. Thesis 
József Höhn M.D. 
Department of Pharmacology and Pharmacotherapy 
Division of Cardiovascular Pharmacology Hungarian Academy of 
Sciences 
and 
Department of Surgery 
Albert Szent-Györgyi Medical and Pharmaceutical Center 
University of Szeged 
Szeged, Hungary 
- 2006 -
I. 
I 
LIST OF PUBLICATIONS RELATED TO THE SUBJECT OF THE THESIS 
FULL PAPERS 
I. Pataricza J, Tóth KG, Penke B, Höhn J, Papp JGy (1995) Effect of selective inhibition 
of potassium channels on vasorelaxing responce to cromokalim, nitroglycerin and nitric oxide 
of canine coronary arteries. 
J Pharm Pharmacol 47: 921-925. Impact factor: 0.848 
n . Hohn J, Pataricza J, Tóth KG, Balogh A, Papp JGy (1997) Nitric oxide activates an 
iberiotoxin-sensitive potassium channel in human saphenous vein. 
Acta PhysiolHung 84: 293-294. Impact factor: 0 
HL Kun A, Pataricza J, Höhn J, Opincariu M, Szécsi J, Papp JGy (1998) The tone 
increasing mechanism of the potassium channel blocker 4-aminopyridine on conductance and 
capacitive type vessels. 
Cardiol Hung 4:183-188. Impact factor: 0 
IV. Pataricza J, Höhn J, Petri A, Balogh A, Papp JGy (2000) Comparison of the 
vasorelaxing effect of cromokalim and the new inodilator, levosimendan, in human isolated 
portal vein. 
J Pharm Pharmacol 52: 1-6 Impact Factor 1.229 
V. Hegedűs Z, Pataricza J, Höhn J, Szécsi J, Bogáts G, Opincariu M, Krassói I, Papp 
JGy (2002) Nifedipin és levosimendan hatása az artéria mammaria interna noradrenalinnal 
kiváltott kontrakcióján az érfal statikus feszülésének függvényében. 
Cardiol Hung 1: 17-21. Impact factor: 0 
VI. Kun A, Pataricza J, Krassói I, Szécsi M, Höhn J, Varró A, Papp JGy (2002) Low 4-
aminopyridine concentration-induced contraction is mediated by neuronal noradrenaline in 
canine saphenous vein. 
Vase Pharmacol 39:7-11. Impact factor: 0.591 
n 
VII. Pataricza J, Krassói I, Höhn J, Kun A, Papp JGy (2003) Functional role of potassium 
channels in the vasodilating machanism of levosimendan in porcine isolated coronary artery. 
Cardiovasc Drug Ther 17: 115-121. Impact factor: 1.129 
VEDL Hohn J, Pataricza J, Petri A, Tóth KG, Balogh A, Varró A, Papp JGy (2004) 
Levosimendan relaxes human saphenous veins by activation of potassium channels. 
Basic & Clinical Pharm and Toxicol 96: 271 -273. Impact factor: 1.342 
ABSTRACTS 
IX. Hohn J, Pataricza J, Tóth KG, Balogh A, Papp JGy (1995) Nitroglycerin activates an 
iberiotoxin-sensitive potassium channel in human saphenous vein. J Moll Cell Cardiol 27: 
A143. 
X. Höhn J, Pataricza J, Balogh A, Papp JGy (1996) The inotropic drug, levosimendan is 
a potent venodilator in canine jugulary and human saphenous veins. J Mol Cell Cardiol 27: 
A385. 
XL Höhn J, Pataricza J, Balogh A, Papp JGy (1997) The novel inodilator drug, 
levosimendan decreases the tone of isolated human saphenous vein via activation of 
potassium channels. J Mol Cell Cardiol 29: ASa80. 
XH. Pataricza J, Höhn J, Petri A, Balogh A, Papp JGy (1998) A calcium sensitizer 
inotropic substance, levosimendan dilates isolated capacitive blood vessels in a glibenclamide 
sensitive manner. J American College of Cardiology 31 (suppl. 5C): A1727. 
XIH. Höhn J, Pataricza J, Balogh A, Papp JGy (1998) Levosimendan-induced venodilation 
at enhanced level of vascular tone. J Mol Cell Cardiol 30: A760. 
XIV. Kun A, Pataricza J, Hohn J, Papp JGy (1998) 4-aminopyridine elevated tone is 
mediated by noradrenaline in isolated canine saphenous vein. J Mol Cell Cardiol 30: A191. 
in 
LIST OF PUBLICATIONS NOT RELATED TO THE SUBJECT OF THE THESIS 
FULL PAPERS 
XV. Sarnyai Z, Hőhn J, Szabó Gy, Penke B (1992) Critical role of endogenous 
corticotropin releasing factor in the mediation of the behavioral action of cocain in rats. 
Life Sci 51: 2019-2024. 
XVI. Petri A, Hőhn J, Hódi Z, Wolfard A, Balogh Á (2002) Pyogenic liver abscess- 20 
years'experience. 
Langenbeck's Arch Surg 387: 27-31. 
( 
XVH. Petri A, Hőhn J, Makula É, László KE, Kocsis SG, Boros M, Balogh Á (2002) 
Experience with different methods of treatment of nonparasitic liver cysts. 
Langenbecks Arch Surg 387: 229-233. 
XVHLBaradnay G, Varga L, Hőhn J, Simonka Zs, Nagy F, Molnár T, Pajor L, Balogh Á 
(2003) Kiterjesztett műtétek a vizeletelvezető rendszert is érintő előrehaladott colorectalis 
carcinomák ellátására. 
Hung Oncol 47: 341-344. 
XIX. Hőhn J, Varga L, Baradnay G, Simonka Zs, Géczi T, Nagy F, Molnár T, Maráz A, 
Kahán Zs, Balogh Á (2003) A lokális recidíva okai a végbélrák radikális műtétei után. 
Hung Oncol 47: 355-360. 
ABSTRACTS 
XX. Farkas G, Márton J, Takács T, Hőhn J (1995) New indications for duodenum-
preserving resection of the pancreatic head. 
G J Gastroenterol 33: A33. 
XXI. Petri A, Karácsonyi S, Hőhn J (1996) Management of benign focal liver diseases 
from surgical point of view. 
Z Gastroenterol 34: A327. 
IV 
XXH. Balogh Á, Varga L, Lázár Gy, Hőhn J, Paszt A, Furák J (1998) Mesorectal excision 
with harmonic Scalpel at rectal cancer. 
Magyar Seb51:Al 77. 
XXHLHőhn J, Varga L, Balogh Á (1998) Gastrointestinal bleeding due to venous 
congestion, as a life threatening complication. 
Magyar Seb 51: A133. 
XXTV.Zöllei I, Hőhn J, Balogh Á (2000) Operative procedures due to anus prae 
complications. 
Magyar Seb 14: A146. 
XXV. Furák J, Tróján I, Szőke T, Hőhn J, Kahán Zs, Tiszlavicz L, Barzó P, Balogh Á 
(2001) Surgical treatment of pulmonary cancer and their brain metastases. 
Hung Oncol 45/3: A51. 
XXVL Furák J, Tróján I, Szőke T, Hőhn J, Morvay Z, Balogh Á (2001) Postpulmonektomiás 
fistula előfordulása és kialakulásának jellemzői. (Postpulmonectomy fistula, its occurence and 
characteristics). 
Magyar Seb 54 (suppl.): A14. 
XXVH. Tróján I, Szőke T, Furák J, Hőhn J, Tiszlavitz L (2001) Resections due to 
pulmonal metastases in a ten year period (1989-1998). 
Hung Oncol 45/3: A221. 
XXVHI. Petri A, Hőhn J, Hódi Z, Balogh Á (2001) Pyogenic liver abscess. Comparison 
of the results of treatment in two periods. 
Z Gastroenterol 39: A414. 
XXIX. Szőke T, Tróján I, Furák J, Hőhn J (2001) Prognostic factors of intrapulmonal 
metastases at patients after lung cancer operation. 
Hung Oncol 45/3: A209. 
V 
XXX. Hőhn J, Hódi Z, Wolfárd A, Petri A (2002) Surgical and oncological treatment of 
liver metastasis of the colorectal cancer. 
Z Gastroenterol 40 (suppl.): A337. 
XXXLMakula É, Hőhn J, László Kókai E, Kocsis Savanya G, Petri A (2002) Expirience 
with different methods of treatment of nonparasytic liver cysts. 
Z Gastroenterol 40 (suppl.): A346. 
XXXII. Petri A, Hőhn J, László Kókai E, Kocsis Savanya G, Balogh Á (2002) Surgery 
of benign liver tumors: Indications and treatment. 
Z Gastroenterol 40 (suppl.): A351. 
XXXm. Wolfárd A, Hőhn J, Hódi Z, Petri A (2002) Evaluation of different treatments 
of pyogenic liver abscess. 
Z Gastroenterol 40 (suppl.): A366. 
XXXIV. Hódi Z, Borbényi Z, Hőhn J, Wolfard A, Petri A (2002) A gyomor lymphomái 
6 éves műtéti anyagunkban. 
Magyar Seb 55: A124. 
XXXV. Petri A, Hőhn J, Makula É, László Kókai E, Kocsis Savanya G, Wolfard A, 
Balogh Á (2002) Nem parazitás májciszta kezelése különböző módszerekkel. 
Magyar Seb 55: A139-140. 
XXXVL Petri A, Hőhn J, Hódi Z, Wolfard A, Balogh Á (2002) Pyogen májtályogok 
sebészi kezelése húsz év tapasztalatai alapján. 
Magyar Seb 55: A140. 
XXXVn. Hőhn J, Hódi Z, Wolfard A, Petri A (2002) Kolorektális rák 
májmetasztázisainak sebészi és onkologiai kezelése. 
Magyar Seb 55: A141. 
XXXVm. Hőhn J, Petri A, Hódi Z, Tiszlavitz L, Balogh Á (2002) A gyomor 
mesenchymalis tumorai klinikánk hatéves anyagában. 
VI 
Magyar Seb 55: A185. 
XXXIX. Petri A, Hőhn J, László Kókai E, Kocsis Savanya G, Wolfard A, Balogh Á 
(2002) Jóindulatú máj daganatok sebészi kezelése. 
Magyar Seb 55: A208. 
XL. Petri A, Hőhn J, László KE, Kocsis SG, Makula É, Wolfard A, Balogh Á (2002) 
Experience with different methods of treatment of nonparasitic liver cysts. 
Hepato-Gastroenterol 49 (suppl.IL): OP92. 
XLI. Petri A, Hőhn J, László KE, Kocsis SG, Wolfard A, Balogh Á (2002) Evaluation of 
different treatments of pyogenic liver abscess. 
Hepato-Gastroenterol 49 (suppl.IL): P101. 
XLH. Hőhn J, Varga L, Zöllei I, Baradnay G, Simonka Zs, Géczi T, Balogh Á (2003) A 
lokális recidíva a rectum carcinoma sebészetében, lehetőségek a megelőzésre. 
Abstract book of Hungarian Coloproctology 1: A45. 
XLHI. Simonka Zs, Varga L, Hőhn J, Baradnay G, Géczi T, Nagy F, Molnár T, Balogh Á 
(2003) Morbus Crohn miatt kezelt betegek sebészi ellátásának elemzése 1993-2002. 
Abstract book of Hungarian Coloproctology 1: A35. 
XLIV. Varga L, Baradnay G, Hőhn J, Zöllei I, Balogh Á (2003) A szövődményes 
diverticulitisek sebészi kezelésének elveiről 
Abstract book of Hungarian Coloproctology 1: A3 9. 
XLV. Kocsárdy E, Hőhn J, Balogh Á (2004) Extensive surgery for advenced cancer of the 
gastrointestinal tract in seriously ill elderly patients. XX th biennal congress of the 
International Society of University Colon and Rectal Surgeons, Abstract book 1: A120. 
XLVI. Hőhn J, Varga L, Simonka Zs, Géczi T, Nagy F, Molnár T, Maráz A, Balogh Á 
(2004) Points influencing the local recurrence of rectal cancer. XX th biennal congress of the 
International Society of University Colon and Rectal Surgeons, Abstract book 1: A75. 
VII 
XLVfl. Simonka Zs, Géczi T, Varga L, Hőhn J, Baradnay G, Nagy F, Balogh Á 
(2004) Quality of life following surgical interventions in Crohn disease. XX th biennal 
congress of the International Society of University Colon and Rectal Surgeons, Abstract book 
1: A67. 
XLVm. Hőhn J, Varga L, Maráz A, Petri A, Balogh Á, Lázár Gy (2005) Preoperative 
radiotherapy as „short irradiation" of patients with rectal cancer, five years experience, 
Hungarian Congress of Coloproctology, Abstract book 1: A23. 
XLIX. Varga L, Nagy F, Simonka Zs, Hőhn J, Baradnay G, Balogh Á, Lázár Gy 
(2005) A Crohn betegség recidívájának sebészi kezeléséről. Hungarian Congress of 
Coloproctology, Abstract book 1: A40. 
L. Hőhn J, Varga L, Maráz A, Petri A, Balogh Á, Lázár Gy (2005) Preoperative 
radiotherapy as „short irradiation" of patients with rectal cancer, five years experience. 
Hepato Gastroenterol 52 (Suppl I) A172. 
LI. Petri A, Hőhn J, László Kókai E, Lázár Gy (2005) Surgery of benign liver tumors: 
indications for treatment in the light of twenty years experience. Hepato Gastroenterol 52 
(Suppl I) A74. 
LH. Petri A, Hőhn J, Varga L, László Kókai E, Lázár Gy (2005) Pyogenic liver abscess: 
Twenty five years experience. Private comparison of results of treatment in two periods. 
Hepato Gastroenterol 52 (Suppl I) A242. 
VIII 
SUMMARY 
The main findings of the present thesis are as follows: 
1. ATP-sensitive (KATP) and large conductance calcium-activated (BKca) potassium 
channels are effectors in modulating the smooth muscle tone in canine coronary artery. These 
ion channels are functionally two distinct targets for activators and inhibitors of potassium 
channels. Nitric oxide activates BKca channels both in the conduit epicardial coronary artery 
of the dog and in the capacitance vein isolated from human subjects. This novel regulatory 
role of nitric oxide in the vascular smooth muscle may have a protective role against 
pathological vasoconstriction through hyperpolarization of the cell membrane. 
2. Voltage dependent potassium (Kv) and BKca channels regulate the basal (resting) tone 
in human, porcine and canine epicardial coronary arteries, respectively. Coronary artery 
samples isolated from the porcine heart can serve as models for studying the functional effect 
of drugs on Kv channels and canine coronary arteries for studying those acting on BKca 
channels. 
3. Apart from endothelial nitric oxide in conduit arteries, the adventitial 
neurotransmission is also able to modulate the tone of vascular smooth muscle in capacitance 
veins. In canine saphenous vein Kv channels regulate noradrenergic neurotransmission and 
profoundly influence the passive (basal) tension of the smooth muscle. 
4. Vasorelaxing mechanism of the inodilator, levosimendan, involves the activation of 
Kv, and, at large concentrations of BKca channels in porcine isolated epicardial coronary 
artery. The mechanism of vasodilation induced by levosimendan depends, at least in part, on 
two other potassium channels functionally differing from the known effect of the drug on 
KATP channels. 
5. The KATP channel activator, cromakalim is able to relax human isolated portal vein. 
Levosimendan is found to be more potent than cromakalim and its mechanism partially 
depends on activation of hyperpolarizing KATP channels. 
6. Levosimendan dilates the human saphenous vein preparations by interacting with 
hyperpolarizing potassium channels, K A T P and BKca. The KATP channels partly mediate the 
IX 
venodilating effect of levosimendan and the presence of intact BKca channels are obligatory 
for the dilating effect of the inodilator. 
7. Vasodilating capacity of the inodilator, levosimendan, depends on the actual value of 
transmural pressure in both the bypass conduit and human internal mammary arteries, 
furthermore in the capacitance canine saphenous vein. In this 'myogenic response' 
hyperpolarizing potassium channels, probably KATP-types, may play some roles. 
X 
ABBREVIATIONS 
4-AP = 4-aminopyridine 
5-HT = 5-hydroxytryptamine 
6-OHDA = 6-hydroxydopamine 
Ach = acetylcholine 
BKca = large conductance calcium activated potassium channel 
BRK = bradykinin 
ChTX = charybdotoxin 
CRO = cromakalim 
cGMP = cyclic guanosine 3,5-monophosphate 
EDHF = endothelium derived hyperpolarizing factor 
FDT = force-displacement transducer (Type F30) 
GLI = glibenclamide 
IBTX = iberiotoxin 
INDO = indomethacin 
KATP = ATP-sensitive potassium channel 
Kca = calcium-dependent potassium channel 
K C 1 = potassium chloride 
KHS = Krebs-Henseleit solution 
KIR = inwardly rectifying potassium channel 
Kv = voltage-dependent potassium channel 
LEVO = levosimendan 
L-NOARG = NG-nitro-L-arginine 
L-VOCC = L-type voltage dependent potassium channel 
NA = noradrenaline 
MS = nisoldipine 
NO = nitric oxide 
NTG = nitroglycerine 
PGF2„ = prostaglandin F2a 
PN = pen recorder (Type 175, KUTESZ) 
TEA = tetraethylammonium 
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1. INTRODUCTION 
Cardiovascular diseases are still at the first place of morbidity and mortality in the 
Western societies. A new class of substances affecting the membrane potential of the heart 
and the circulatory tree are of current interest. Possible targets of these natural or synthetic 
compounds are hyperpolarizing potassium channels located on the surface of the smooth 
muscle membrane. In the vasculature a large background potassium current renders the 
smooth muscle in a resting, hyperpolarized state. This ion current inhibits the entry of 
extracellular calcium ions into the intracellular space of the arterial and venous smooth 
muscle. Since calcium ion flow through the voltage-operated calcium channels is a common 
mechanism of elevated tone in the blood vessels, activation of potassium channels would be a 
therapeutic approach for inducing vasodilation independently of the underlying pathological 
insult. 
Potassium channels by hyperpolarizing the smooth muscle membrane regulate both 
the arterial and venous tones. Activators and inhibitors of potassium channels may have 
therapeutic values in several cardiovascular disorders, including hypertension, atherosclerosis, 
heart failure, diabetes, and some types of angina pectoris with dynamic stenosis. Potassium 
channels are the most diverse ion channels and their localizations and functions depend on the 
animal species and types of blood vessels. Therefore, investigations of these channels on 
human blood vessels are essential. 
There are three main types of potassium channels in the vascular system, the ATP-
sensitive potassium channel (KATP) in the family of inwardly rectifying potassium channels 
(KM), the voltage dependent (Kv) and the calcium activated potassium channels (Kca). In our 
experiments we focused our attention on the regulatory roles of these potassium channels 
exerted on the tone of some blood vessels including human ones. Specific activators and 
inhibitors of potassium channels as well as the possible involvement of the function of 
potassium channels in the vasodilating mechanism of nitric oxide and that of the new 
inodilator drug, levosimendan, were investigated by using isolated conduit arteries and 
capacitance veins. 
1.1. Anatomical summary of blood vessels 
Arteries and veins are muscular blood vessels and their walls are composed of three 
layers: tunica intima, media and adventitia. On the border between the media and the intima 
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as well as the media and adventitia there are sheets of elastic fibers. They show a common 
general pattern of organization and are made up of similar tissue materials (Basar & Weiss 
1981, Rhodin 1980). The intima consists of a single layer of endothelial cells which is in 
contact with the blood and a thin subendothelial layer with fibroblasts and collagen fibers. 
The endothelium interacts with smooth muscle cells by the synthesis and secretion of 
vasoactive mediators or by direct contact via gap junctions. 
The media of large central arteries including the conduit type of side branches is built 
up of smooth muscle cells and connective tissue, elastic and collagen fibers. The outermost 
layer is the adventitia, which may, in some places, be as thick as the media and it is composed 
of loose connective tissue containing relatively sparse elastin and collagen fibers running in a 
predominantly longitudinal direction. The adventitial layer carries the majority of sympathetic 
nerves. The density of innervations varies widely and probably reflects the contribution of the 
individual vessels to centrally controlled responses. 
1.2. Functional differentiation of vascular bed 
Coordination and integration of cardiac and peripheral vascular activity are essential 
for the maintenance of homeostasis in the organism. The peripheral circulation plays an 
essential role in this interplay and can be classified in different categories: conduit, 
capacitance and resistance blood vessels (Basar & Weiss 1981, Safar 1996, Witzleb 1989). 
1.2.1. The arteries, as conduits, have the role of carrying an adequate supply of blood from 
the heart to the peripheral organs and tissues of the body. The efficiency of the arterial conduit 
function depends on the arterial caliber and the constancy of mean blood pressure. 
1.2.2. Capacitance vessels (mainly the venous section) can take in or pass on large volumes 
of blood with no marked effects on the other parameters of the circulation. They can thus act 
as blood reservoirs. Changes of smooth muscle tone in these vessels can produce 
haemodinamically important shifts in regional blood content and thus influence venous return 
and cardiac output. 
1.2.3. Resistance vessels determine the overall resistance function, and hence, blood 
flow. The greatest resistance to flow is in the precapillary region (terminal arteries and 
arterioles). Activity of the smooth muscles in these arteries is the decisive factor in the 
regulation of volume flow within each vascular bed, as well as in the distribution of the 
cardiac output among the various organs. The postcapillary resistance is determined by the 
venules (and veins). 
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1.3. Blood vessel regulation via vasoactive agents 
The smooth muscle tone is regulated by different vasoconstrictor or vasodilator agents 
regulating the diameter of blood vessel and hence can induce haemodynamic changes in the 
perfusion of the tissue. Important agents playing a role in the regulation of blood vessels 
involved in this study are the following: 
5-hydroxytryptamine(5-HT): 5-HT has complex effect on the cardiovascular system, 
including direct and indirect vasoconstriction or vasodilation (Martin 1994). 5-HT is a potent 
vasoconstrictor agent in coronary arteries and has been used in the provocation of coronary 
vasospasm (Perez et al 1983). Moreover, 5-HT can be taken up by adrenergic nerve endings 
of some blood vessels and can be released from them together with NA (Szabo et al 1991). 
Nitric oxide (NO): The endothelium-derived relaxing factor, which was firstly 
characterized by Furchgott and Zawadzki in 1980, and identified as NO (Furchgott 1988, 
Ignarro et al 1988), induces smooth muscle relaxation due to the activation of guanylyl 
cyclase. The complex mechanisms involved in the synthesis and effect of NO is well 
established (Pearson & Vanhoutte, 1993). Moreover, NO, besides adenosine, participates in 
coronary artery autoregulation (Ishibashi et al 1998). 
Endothelium-dependent hyperpolarizing factor (EDHF): It has been demonstrated that 
endothelium-dependent relaxation induced by acetylcholine (Ach) and bradykinin (BRK) 
persists in the presence of cyclo-oxygenase or NO synthase inhibitors (Prieto et al 1998, 
Krassoi et al 2000) and called endothelium-dependent hyperpolarizing factor. This is an 
important mediator of vascular relaxation in different vascular beds, however, the chemical or 
physical nature of EDHF is unknown (Campbell & Gauthier 2002). 
Prostaglandin p2a (PGF2J: This metabolite of arachidonic acid is a powerful 
contractile mediator in the coronary circulation. 
Noradrenaline (NA): The sympathetic neurotransmitter in most vessels activates 
postjunctional a-adrenoreceptors initiating contraction of the vascular smooth muscle cells 
and thus vasoconstriction. However in several vascular beds, e.g. coronary arteries, activation 
of postjunctional P-adrenergic receptors by liberated NA induces vasodilation under 
physiological conditions (Vanhoutte et al 1981). 
Potassium and calcium ion channels (K and Ca channels): In addition to stimulation 
of receptors located on the cell membrane, the other main cellular mechanism by which 
vascular smooth muscles can be activated is membrane depolarization. Opening of potassium 
channels leads to diffusion of potassium ions out of the cells, causes membrane 
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hyperpolarization and decreases the activation of voltage-gated Ca2+ channels. The decrease 
in intracellular Ca2_r concentration results in vasodilation (Jackson 2000). 
1.4. Role of potassium channels in the modulation of smooth muscle cells 
Smooth muscle cells are the most intensively investigated vascular cells. Membrane 
potential of smooth muscle cells appears to be an important regulator of vascular tone. 
Vascular smooth muscle cells express 4 different types of potassium channels: Kv, BKca, 
KATP and G-protein coupled inward rectifier potassium (GIRK) channels (Nelson & Quayle 
1995, Hobbs et al 2004). The opening of potassium channels in the membrane of smooth 
muscle cells increases potassium efflux out of the cells leading to membrane 
hyperpolarization. Closure of potassium channels has the opposite effect. Hyperpolarization 
closes the voltage-gated Ca2_r channels, which causes vasodilation, whereas depolarization 
opens them inducing vasoconstriction (Jackson 2000). Kv channels have been identified in 
smooth muscle cells obtained from different types of blood vessels. 4-AP is the known most 
selective inhibitor of Kv channels in vascular smooth muscle. Inhibition of the 4-AP-sensitive 
potassium channels induces depolarization and vasoconstriction (Nelson & Quayle 1995, 
Halliday et al. 1995, Knot & Nelson 1995, Nelson & Brayden 1993). The KCa channels are 
found in smooth muscle cells obtained from different types of vascular beds. These channels 
are activated by an increase in intracellular Ca2+. Blockade of these channels by 
tetraethylammonium (TEA) leads to membrane depolarization and vasoconstriction (Nelson 
& Quayle 1995; Silva et al 1994; Cook 1989). The role of K A T P channels in the regulation of 
membrane potential is controversial. Glibenclamide (GLI), the selective blocker of KATP 
channels, caused arteriolar constriction in several microcirculatory beds, but in other blood 
vessels its effect is not obvious under physiological conditions. The channel seems to be 
involved in the metabolic regulation of blood flow and is activated in pathological conditions, 
such as hypoxia (Nelson & Quayle 1995). The role of KIR channels in the regulation of resting 
membrane potential and tone remains unclear. The KIR channel in arterial smooth muscle is 
very sensitive to inhibition by extracellular Ca2+. Recent evidences suggest that potassium-
induced vasodilation in resistance arteries is mediated by KGR channels but this channel does 
not play a functional role in the regulation of tone in conduit blood vessels (Nelson & Quayle 
1995). 
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1.5. Role of potassium channels in the vasodilating effect of endothelial nitric oxide 
The vascular endothelium is located at the interface between the circulating blood and 
vessel wall. Endothelial cells, unlike nerve and smooth muscle cells, are classified as 
nonexcitable cells since they have never been observed to produce action potentials. The 
endothelium interacts with smooth muscle cells by the synthesis and secretion of vasoactive 
mediators including nitric oxide and, possibly, EDHF/s. Although in most vascular beds, 
EDHF is considered to be a sole entity, it was suggested that endothelial NO is also able to 
hyperpolarize the smooth muscle (Tare et al 1990). NO is known to activate Ca2+-activated 
potassium channels on the membrane of the smooth muscle which may differ from those 
potassium channels that are located on the endothelial membrane (Prieto et al 1998; Nilius et 
al 1997; Simonsen et al 1995). 
1.6. Role of potassium channels in the regulation of adrenergic nerves 
Blood vessels are innervated by sympathetic nerves. NA, released from the 
sympathetic nerve terminals, is the main transmitter in the adrenergic nervous system. NA 
activates postjunctional a-adrenoreceptors, which initiates the contraction of vascular smooth 
muscle. The release of this transmitter from presynaptic nerve terminal depends on the 
electrical responses of presynaptic membrane. Potassium channels are important participants 
of electrical changes in membrane potential leading to transmitter release (Vanhoutte et al 
1981). 
Similarly to the arteries, the tone of the veins is also controlled by the sympathetic 
nervous system. Kv channels located on the perivascular nerves were suggested to regulate 
the tone of the venous smooth muscle indirectly by releasing NA (Kato & Takata 1987). Kca 
channels were also proved to regulate NA release from the perivascular nerves of arteries 
(Marin et al 1985; Nally & Muir 1992), however, the functional roles of autonomic neuronal 
KIR channels including the K A T P subtype could not be detected (Deist et al 1992; Lee et al 
1995; Roeper & Pongs 1996; Ponce et al 1996). 
1.7. Effect of simulated transmural pressure on the activation of potassium channels 
Acute changes in transmural pressure of blood vessels can influence the activity of 
potassium channels and thus the effect of potassium channel openers. In an in vitro organ 
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bath, passive stretch applied perpendicular to the axis of an artery or vein represents the 
increase of transmural pressure being physiological at 80-100 mmHg in a large conduit artery 
and 10 mmHg or lower in a capacitance vein. An increase in transmural pressure causes 
depolarization and under these conditions, opening of K A T P channels can induce a much larger 
change in membrane potential than in relaxed arteries (Daut et al 1994). Stretching of isolated 
veins also induces an acute myogenic response and changes the membrane potential (Bérezi et 
al 1992; Monos et al 1993). Other mechanosensitive ion channels known to involve in stretch-
responses are the following: non-selective cation channels, Kca channels and tandem-pore 
potassium channels (Wu et al 2003; Lee et al 2000; Bang et al 2000). 
1.8. Aims of the present study 
On the basis of these findings, BKca, Ky and KATP channels seem to be important 
potassium channels in the regulation of the tone of smooth muscle cells. The main purpose of 
the present study was to determine the functional role of KATP, BKca and Ky channels using 
some potassium channel blockers and as well as known putative potassium channel activators. 
The aims were subdivided as follows: 
• Investigation of the function of potassium channels in conduit and capacitance types of 
blood vessels by using activators and inhibitors. 
• Investigation of the role of BKca channels in the vasodilating effect of NO. 
• Investigation of the role of Ky channels in the regulation of NA release. 
• Investigation of the role of KATP and BKCA channels on the venous tone. 
• Characterization of potassium channels involved in the vasodilating mechanism of the 
inodilator, LEVO, in coronary artery. 
• Investigation of the effect of LEVO in relation to the simulated transmural pressure 
of the vessel wall. 
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2. MATERIALS AND METHODS 
2.1 MEASUREMENTS OF ISOMETRIC TENSION IN CONDUIT AND 
CAPACITANCE TYPES OF BLOOD VESSELS 
2.1.1 Investigations of BKc& channel 
2.1.1.1. Canine coronary arterial preparations 
Mongrel dogs of either sex, weighing, 9-15 kg were anesthetized with sodium 
pentobarbitone (30 mg/kg, i.v.) and heparinized (1000 IU/kg). The heart was excised and 
placed into a Krebs-Henseleit solution (KHS) of the following composition (mM): NaCl 120, 
NaHC03 20, KC1 4.1, KH2PO4 1.2, MgCl2 1.2, CaCl2 1.5 and glucose 11 (pH 7.4). Rings 
(1.1-1.9 mm o.d., 5 mm width) from the descending and circumflex branches of the left 
coronary artery were isolated from the heart. Endothelium was removed by gently rubbing the 
endothelial surface with a stainless steel wire covered with a cotton swab. Preparations were 
then mounted in water-jacketed baths containing 2 ml KHS bubbled with 95% 02-5% C02 
gas mixture at 37 °C, and that will be used also in the following investigations. The isometric 
tension was recorded with a force-displacement transducer (Hugo Sachs Elektronic, Type 
F30, Germany, Fig. 1) and mechanical responses of arterial rings were displayed by means of 
a pen recorder (Type 175, KUTESZ, Hungary) as in the following investigations in 
conductance and capacitance vessels. Rings were stretched up to 10 mN and allowed to 
stabilize for 45 min. This tension was readjusted to 10 mN during equilibration. 
Following equilibration, contractions were induced by 25 pM prostaglandin F2a (PGF2a), and 
at the maximum amplitude of contraction 1 pM acetylcholine (Ach) was applied. Only those 
arterial preparations were used for the experiments that responded with contraction after 
addition of 1 pM Ach. This protocol served as evidence for functionally de-endothelialized 
arterial preparations, indomethacin (INDO, 10 pM) was used in all experiments to exclude the 
effect of endogenous prostaglandins on the arterial tone. 
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Two parallel rings isolated from the same branch of a coronary artery were used for 
measurement of contraction and relaxation. After checking the functional denudation with 
Ach, the rings were washed with KHS. One arterial ring was exposed to solvent and served as 
a control while the other was exposed to a potassium channel blocker [90 nM iberiotoxin 
(fBTX) or 30 pM glibenclamide (GLI)] for 30 min. Contractions were induced again by the 
addition of 25 pM PGF2tt to both rings. At the steady state of contraction cromakalim (CRO) 
was applied in cumulative manner. The same arterial rings were used for further contractions. 
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In another series of experiments the contraction of the rings was induced with low 
(14.4-20.4 mM) or higher (35.4-40.4 mM) concentrations of depolarizing potassium chloride 
(KC1). Elevation of potassium concentration in the solution was made by substituting NaCl 
with equimolar KC1 in the KHS medium. Experiments were started with 14.4 mM KC1 
medium and, if it was necessary, replaced with higher concentrations of KC1 until it was 
enough to induce contraction. Relaxation by exogenous nitric oxide (NO) in the presence and 
absence of 90 nM IBTX was examined. 
Preparation of NO solution (about 1.6 mM): a saturated solution in double-distilled 
water was prepared using a slight modification of a previously described method (Menon et 
al. 1991). Water in a 10-ml vacutainer tube was deoxygenated by purging with 100% nitrogen 
for 1 hour and then bubbled with nitric oxide for 20 min. For diluting nitric oxide, 100 pi of 
this solution was transferred with a gas tight syringe (Hamilton, Bonaduz, Switzerland) to 
another tube containing 10 ml deoxygenated water and used for experiments within 1.5 h. 
Relaxation with nitric oxide (100-800 nM) was induced at the steady state of KC1 contraction 
in control rings and in rings pretreated with IBTX as described above. 
2.1.1.2. Hitman saphenous vein preparations 
Vena saphena magna was obtained from patients suffering from varicose vein disease 
and undergoing surgical intervention. The experimental protocol complied with the 
Declaration of World Medical Association proclaimed in Helsinki and was approved by the 
Human Ethical Review Board of the Albert Szent-Györgyi Medical University (No. 164/2002 
OEj). Visually intact parts of the saphenous veins were carefully excised and placed into an 
ice-cold KHS solution. Rings of 5 mm width were cut from the vein. After cleaning from the 
connective tissue rings were mounted in parallel in two water-jacketed baths, data handling 
occurred as described above (2.1.1.1.). The rings were stretched up to 8-10 milliNewton (mN) 
and allowed to stabilize for 30 min. This tension was continuously readjusted to the basal 
tension during equilibration. 
NO was obtained by reducing NaN02 in the following medium: (140 mM Na2S04, 
100 mM Nal and 270 pi concentrated H2S04 in 50 ml double distilled water. This solution 
was bubbled with 95% N2 and 5% C02 gas mixture for 45 min in an air-tight vacutainer tube. 
NaN02 was injected into this 0 2 free solution to result in 100 pM stock solution. 
After 30 min equilibration of the two venous preparations with 90 nM EBTX and with 
the corresponding volumes of solvent contractions were induced with 5-hydroxytryptamine 
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(5-HT, 0.125 riM). At the steady-state contractions cumulative concentrations of NO (50-1550 
nM) were applied. 
2.1.2 Investigations for Kv channel 
2.1.2.1. Human coronary arterial preparations 
Human coronary arteries were prepared from parts of undiseased donor hearts 
unsuitable for transplantation from which the aortic and pulmonary valves had been 
previously excised for homograft-valve surgery. Before implantation of the hearts the patients 
did not receive any medication except for dobutamine, furosemide and plasma expanders. The 
experimental protocol complied with the Declaration of World Medical Association 
proclaimed in Helsinki and was approved by the Human Ethical Review Board of the Albert 
Szent-Györgyi Medical University (No. 51-57/1997 OEj). The hearts were stored in a 
cardioplegic solution, which had the following composition (in mM): NaCl 110, KC1 16, 
MgCl2 16, CaCl2 1.2, NaHC03 10, at 4 °C and used for experiments within 12 hours. The 
carefully removed human epicardial coronary arteries were cleaned from the connective tissue 
and the blood vessels were cut into 5 mm rings. Then rings were placed into the organ bath, 
data handling took place as describerd above (2.1.1.1.). Rings were stretched up to 10 mN, 
and equilibrated for 45 min (the medium was changed in every 15 min). 
Concentration-response curves to 4-aminopyridine (4-AP, 12.5 nM-187.5 fiM) were 
obtained using the drug in a cumulative manner in the organ bath after the equilibration time. 
After the 4-AP contraction had been completed 0.1 and 1 pM nisoldipine (NIS) were added. 
2.1.2.2. Canine saphenous vein preparations 
The experiments (and also further investigations on animals) were performed by the 
permission of the Local Committee for Animal Research of Albert Szent-Györgyi Medical 
University (No. 71/1999). Mongrel dogs of either sex were heparinized (500 IU/kg iv) and 
anesthetized with sodium pentobarbital (30 mg/kg iv). Lateral saphenous veins were taken 
out, carefully cleaned from connective tissue and cut into 5 mm ring segments for 
investigation. Experiments were performed in the absence of vascular endothelium. Removal 
of the endothelium was achieved mechanically by using a cotton swab on a glass rod. 
Functional endothelial denudation was evidenced by lacking vascular relaxation after 
administration of 1 pM bradykinin (BRK). Paired venous rings were investigated in parallel. 
Vein segments were mounted in isolated organ baths and data handling occurred as described 
above (2.1.1.1.). 
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The 5-mm ring segments were stretched up to 10 mN and equilibrated in 2 ml KHS for 
45 min. After the equilibration of the venous rings under 10 mN stretch concentration-
response curves to 4-AP (0.0125-5 pM) were obtained by adding the drug to the tissue bath in 
a cumulative manner. Following the maximum contraction induced by 4-AP the preparations 
were washed three times and incubated with 1 mM noradrenaline (NA) for 10 min. Loading 
procedure of the preparations with NA involved the addition of 1 mM NA for 10 min 
followed by thorough washing out (at least three times) of the catecholamine from the organ 
bath. After washing out this large concentration of NA, the changes of tone were monitored 
again by repeated exposure to 4-AP. 
In parallel experiments 6-hydroxydopamine (6-OHDA, 0.5 mM, 3 h incubation) was 
used to destroy the noradrenergic nerve endings before the addition of 4-AP. 
2.1.3. Investigations with levosimendan 
2.1.3.1. Porcine coronary arterial preparations 
Porcine hearts were obtained from the local slaughterhouse and transported to the 
laboratory in ice-cold KHS. The experimental protocol was approved by the Ethical Review 
Board of the University of Szeged, Hungary (I-74-3/2002.MAB.sz.). Epicardial coronary 
arteries of the descending branch were used for the experiments. 5 mm-long ring segments 
were cut out of the coronary artery, cleaned from the surrounding connective tissue and the 
endothelium was mechanically removed (denudation procedure in the case of canine 
saphenous vein (2.1.2.2)). Then two rings were submerged into water-jacketed baths for 
isometric tension recordings. Only those coronary preparations were used for the experiments 
that responded with contraction to the addition of 1 pM BRK. Two coronary rings of each 
porcine heart were mounted separately in isolated tissue baths and data handling took place as 
described above (2.1.1.1.) The preparations were stretched up to 30 mN (because the wet 
weight of the porcine coronary preparation is three fold heavier than that of the human ones) 
and allowed to equilibrate for 90 min. Within this equilibration period the incubation medium 
was changed in every 15 min and a response to 30 mM potassium chloride (KC1) rich solution 
was produced in order to stabilize the contractile activity of the blood vessels. In experiments 
designed to determine if CRO and LEVO caused the porcine isolated coronary artery to relax, 
after equilibration of the pairs of ring segments, contractions to 20 mM KC1 were induced. An 
additional 15.8 mM KC1 was added to the medium because the KHS had already contained 
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4.2 mM KC1. When the steady-state contraction amplitude produced by KC1 had developed, 
one of the rings was cumulatively exposed to LEVO (0.009-3.2 pM) or CRO (0.0125-5 pM). 
The other ring was at first preincubated with 1 pM GLI 30 min before the addition of the 
contractile agent, KC1, and the protocol was then followed by the cumulative administration 
of either LEVO or CRO. 2 pi solvent of GLI was without effect on the parallel ring. 
In another series of experiments the capacity of the other potassium channel blocker, 
tetraethylammonium (TEA), to influence relaxations caused by CRO and LEVO was 
assessed. The protocol was similar to that described above, except that the concentration-
response curves for both LEVO and CRO were determined in the presence of 2 mM TEA and 
of the corresponding solvent (20 pi distilled water) of the potassium channel blocker (5 min 
preincubation before addition of KC1). 
In a third series of experiments the ability of the Kca channel blocker, 100 nM IBTX 
(30 min before KC1), and that of the Kv channel inhibitor, 0.5 mM and 5 mM 4-AP (10 min 
before KC1) to influence the coronary relaxations by LEVO was investigated. During this 
protocol, a parallel control with the solvents of the potassium channel blockers (20 pi distilled 
water of IBTX and 20-200 pi of 4-AP) was also investigated. 
2.1.3.2. Human internal mammary artery preparations 
Internal mammary arteries (IMA) were obtained atraumatically from patients who 
were operated on due to coronary occlusion, healed with mammarian graft insertion. The 
experimental protocol complied with the Declaration of World Medical Association 
proclaimed in Helsinki and was approved by the Human Ethical Review Board of the Albert 
Szent-Györgyi Medical University (No. 51-57/1997 OEj). Before explantation of the vessels 
patients had got usually medication as follows: P-adrenergic blocking agents, angiotensin 
converting enzyme inhibitors, Ca antagonists and nitrates. 
The carefully removed internal mammary arteries were cleaned from the connective tissue, 
and the endothelium was removed by carefully rubbing the endothelial surface with a 
stainless steel wire covered with a cotton swab. Then vessels were cut into 5 mm rings and 
were placed into the organ bath and data handling occurred as described above (2.1.1.1.). 
Rings were stretched up to 23 mmHg and 46 mmHg, according to the Laplace law 
[(P=Tw*2II/I, where P is the intraluminal pressure, Tw is wall tension calculated from the 
initial stretch applied (F) and from length of vessel segment (L), that is Tw= F/L (mN/mm2), 
and I is internal circumference of the vessel wall (mm), values obtained in Pascal were 
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converted into mmHg)], and equilibrated for 45 min. After equilibration time rings were 
contracted with NA (1-7 pM) cumulatively, and at the end point of the maximal tone LEVO 
was cumulatively added into the organ bath (0.3-0.6 pM). After all, the organ bath was 
washed out three times with KHS, and the experiment was repeated at 92 mmHg prestretched 
vessels. After repeated washing out, the functionally damaged endothelium was proved to 
have no effect of 0.1 pM BRK on the tone. 
2.1.3.3. Canine saphenous vein preparations 
Lateral canine saphenous veins were used in this protocol. The method was similar to 
that written in chapter 2.1.2.2. In the first series of experiments, two parallel rings were 
mounted in separated water jacketed baths; one of them was stretched up to 5mN, the other 
one to lOmN. These values of intraluminal stretching were considered as moderate and high 
venous blood pressures (10 and 20 mmHg) according to the calculations by the Laplace law 
(2.1.3.2.). 
After 45 min equilibration, at the steady state contraction caused by 3.25pM NA, 
LEVO was cumulatively administered into the organ bath (0.03-3.4 pM). 
In the second series of experiments the two parallel measurements were performed at 
the same level of vascular tone. At the first third of the equilibration 1.5pM GLI was added to 
one of the rings and corresponding solvent to the other one. After another 30 min NA 
contraction was also induced. 
2.1.3.4. Human portal vein preparations 
Portal veins were prepared from liver transplants of patients, aged 17 to 62 years 
(average age 44± 14 years) who had died accidentally. Segments (2.2 cm long) of portal vein 
were removed from those livers deemed unsuitable for transplantation and were stored for up 
to 4 h in Bretschneider solution: (NaCl (15 mM), KC1 (9mM), potassium hydrogen-2-
oxoglutarate (1 mM), MgCl2x6H20 (4 mM), histidine HClx H20 (18 mM), histidine (180 
mM), tryptophan (2 mM) and mannit (30 mM). Only macroscopically healthy veins were 
used. Veins were placed into an ice-cold KHS. The venous segments were prepared in the 
clinical surgery and transported to the experimental laboratory within 15 min. The vessels 
were then dissected free of perivascular tissue and cut into rings (5 mm long). 
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Two rings of each portal vein were mounted separately in water-jacketed baths and 
data handling occurred as described above (2.1.1.1.). Preparations were stretched until near-
maximum contractile responsiveness to NA was reached at 40 mN basal tension. Each ring 
was allowed to equilibrate for 45 min before initiation of experimental procedures and during 
this period the incubation medium was changed every 15 min and the resting tension was 
readjusted. 
In experiments designed to determine if CRO and LEVO cause the human isolated 
portal vein to relax, after equilibration of the pairs of ring segments, contractions to 10 pM 
NA were induced. When steady-state contraction amplitude produced by NA had developed, 
one of the rings was cumulatively exposed to LEVO (0.01-1.27 pM) and the other ring was 
treated with the corresponding volumes of the solvent (1-64 pi). The same procedure was 
used with another pair of venous rings obtained from the same liver, except that, instead of 
LEVO, CRO (0.2-47 pM) and its solvent (0.5-125 pi) were administered cumulatively at the 
steady-state of NA-induced contraction. In the latter case, the largest volume of solvent 
produced relaxations in some cases an effect which was deduced from comparisons of the 
magnitude of relaxation induced by CRO. 
In another series of experiments the capacity of GLI (1.5 and 15 pM) to decrease 
relaxations caused by CRO and LEVO was assessed. The protocol was similar to that 
described above, except that concentration-response curves for either CRO or LEVO were 
determined in the presence and absence of 1.5 pM GLI. One of the portal rings was incubated 
with the low concentration of GLI, the other ring with the solvent of the blocker 30 min 
before the addition of NA. After completing the agonist-response curves for CRO and LEVO, 
the ring not treated with GLI was washed three times and incubated with 15 pM GLI for 30 
min. Then steady-state contraction was induced by NA and another agonist-response curve 
was obtained. 
2.1.3.5. Human saphenous vein preparations 
Vena saphena magna was obtained from patients suffering from varicose vein 
diseases, as it was described before (2.1.1.2.), but the equilibration time was 45 min. 
After 45 min equilibration, 15 pM GLI was added to one of the rings and 30 pi solvent 
of GLI to the other one. After 30 min incubation, contraction was induced by exposing the 
two parallel venous preparations to 0.125 pM 5-HT. At the steady-state contraction, 0.04-2.8 
pM concentrations of LEVO were cumulatively applied. LEVO was usually added to the 
tissue bath at intervals of 5-6 min. 
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In another series of experiments, instead of GLI, 90 nM IBTX or its solvent (18 pi 
double distilled water) were used for preincubation of the venous rings for 30 min. Then, 
LEVO, in concentrations of 0.04-2.8 pM, was cumulatively added to the preparations. 
2.2. DATA ANALYSIS AND STATISTICAL COMPARISONS 
The decrease of the venous tone caused by NO, CRO or LEVO was expressed as the 
percent of the 5-HT, KC1, PGF2a, or NA-induced steady-state contraction amplitudes. Results 
are expressed as mean ± s.e.m. and n refers to the number of venous or arterial rings obtained 
from different animals or human organs. One-way analysis of variance with repeated 
measures was used to determine if significant differences existed between groups. When 
analysis of variance showed significant differences, the Newman-Keuls test was performed to 
determine differences between individual values. Values for 50 % effective concentration 
(EC50) were obtained by fitting the exponential equation of 100/{l+exp [b*(x-c)]} to 
individual values, in that 'b' is the slope and 'c' is EC50 of the concentration response curve. 
In another experiments a*x/(x+b) was fitted to concentration response curves, where 'a' is 
maximum (Emax) and 'b' is the EC50 value of the curve. 
2.3. DRUGS AND OTHER AGENTS 
Drugs used in the present study were the following: 
KHS solution (composition in mM: NaCl 120, NaHC03 20, KC14.1, KH2P04 1.2, MgCl2 1.2, 
CaCl2 1.5 and glucose 11 (pH 7.4) Reanal, Budapest, Hungary), nitric oxide, NaN02, Na2S04, 
Nal, H2SO4, 4-aminopyridine, 5-hydroxytryptamine, 6-hydroxydopamine hydrobromide, 
acetylcholine, creatinine sulfate complex, glibenclamide, , indomethacin, L-noradrenalin-L-
bitartrate, prostaglandin F2a (Sigma, St. Louis, MO), NG-nitro-L-arginine (L-NOARG), 
tetraethylammonium HC1, sodium nitrite, pentobarbital sodium (Serva). Cromakalim was 
obtained from Beecham Pharmaceuticals (Harlow, UK). Iberiotoxin was synthesized by 
Gabor K. Toth (Dept of Med Chemistry, Szeged, Hungary), and it was dissolved in double-
distilled water to give a concentration of 3 pM. 
Levosimendan was a gift from Orion-Farmos, Espoo, Finland., and it was prepared 
daily by dissolving it in 70% ethanol (0.21mM in stock solution). CRO and GLI were 
dissolved in double distilled water containing 20% dimethylsulfoxide and 20% ethanol. The 
concentrations of CRO and GLI were 0.45 mM and 1 mM in the stock solutions, respectively. 
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TEA, IBTX and 4-AP were dissolved in distilled water and the concentrations of stock 
solutions were: 1 M, 10 pM and 50 mM, respectively. 
NA was dissolved in 0.9% NaCl with 10 mM ascorbic acid, resulting in 1 mM NA in the 
stock solution. PG F2a was dissolved in 70% ethanol (stock solution 10.5 mM). Indomethacin 
was dissolved in 96% ethanol at a concentration of 1 mM. 
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3. RESULTS 
3.1. Investigations of the effect of potassium channel blockers on BKca channel 
3.1.1. Effect of CRO and NO on canine coronary arteries 
3.1.1.1. Effect of CRO in the absence and presence of GLI. Functional BKca channel 
differs from the KIR (KATP) channel. 
The activator of K A T P channels, CRO, produced a dose-dependent relaxation of 
coronary arterial rings in a concentration range of 0.15-9.6 pM (Fig. 2.). The calculated E C 5 0 
of CRO was 0.41 pM in the absence of GLI. Preincubation of coronary rings for 30 min with 
30 pM GLI did not affect the resting tone of the arteries (control=0.8±l.l%, GLI=1.7±2.0%, 
n=7, p>0.05; percent increase of tone compared with the amplitude of steady-state contraction 
induced by PGF2a) nor was there an effect on the magnitude of contraction induced by PGF2a 
(control=49.4±6.0 mN, GLI=53.8±7.4 mN, n=7, p>0.05). However, GLI almost completely 
inhibited the relaxation induced by CRO. 
Figure 2. Effect of GLI on the 
relaxant responses to CRO in isolated 
rings of canine coronary arteries. 
Paired arterial rings prepared from the 
same heart were pretreated with either 
30pM GLI ( • ) or the corresponding 
volume of vehicle (o) 30 min before 
addition of 25pM PGF2a. At the 
steady-state contraction induced by 
the PGF2a, CRO was applied 
cumulatively. Each value represents 
the mean of percent relaxation 
obtained in seven coronary rings from 
different dogs. Vertical lines show the 
s.e.m. **P<0.01, ***P<0.001 
compared with vehicle-treated group. 
TOO -
T T 
8 0 . 
x 
2 
1 / 
c 
.2 6 0 - Y A « y 
F 
40 
• y 
2 0 y 
0 V i l L l l - U J 
1 1« 1 ' | 
0 . 0 1 0 . 1 1 10 
Cromakalim (pM) 
21 
3.1.1.2. Effect of CRO in the absence and presence of IBTX. 
After 30 min preincubation with 90 nM IBTX, the specific inhibitor of BKca channels, 
the resting tone of the arteries was slightly but significantly increased compared with control 
(control=1.2±1.2%, IBTX-treated= 10.4±2.5%, n=7, p<0.05). The maximum contraction 
amplitude produced by PGF2a did not differ between the IBTX-treated group and the control 
(control=55.6±5.3 mN, IBTX-treated=53.3±7.8 mN, n=7, p>0.05). Preincubation of coronary 
arteries with IBTX for 30 min did not change the vasodilating potency of CRO ( E C 5 0 
CRO=0.43 pM, EC50 CRQ+IBTX=0.42 pM, Fig. 3.). 
Figure 3. Effect of IBTX on the 
relaxation induced by CRO in 
isolated rings of canine coronary 
arteries. One of two arterial rings was 
pretreated with 90 nM IBTX (•) and 
the other was exposed to the solvent 
of IBTX (o). After 30 min 
preincubation with IBTX, contraction 
was induced with 25 pM PGF2a. At 
the steady-state of contraction, CRO 
was added in a cumulative fashion. 
Values are mean±s.e.m. each 
representing seven coronary 
preparations obtained from different 
dogs. 
3.1.1.3. Effect of exogenous NO on KC1 depolarized coronary rings. 
Threshold concentration of KC1 necessary to induce contraction varied between 14.4 
and 20.4 mM. When the KC1 concentration was 14.4-20.4 mM, IBTX significantly enhanced 
the amplitude of contraction (control=11.6±4.3 mM, KCl=25.3±3.7mM, n=7, p<0.05). The 
results obtained with NO are summarized in Table 1. Relaxation by 100 and 200 nM NO was 
significantly inhibited by IBTX. The effect of higher concentrations (400-800 nM) of NO was 
not influenced by the toxin. Depolarization of the artery with 35.4-40.4 mM KC1 resulted in a 
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contraction amplitude of 35.7±7.0 mN (control) that did not differ from that of the IBTX 
pretreated group (38.4±4.7 mN, n=6, P>0.05 compared with control). Amplitudes of 
relaxation by NO were significantly smaller at high KC1 concentrations compared to low 
ones. The inhibitory effect of IBTX on NO-induced relaxation disappeared at 35.4-40.4 mM 
of depolarizing KC1. 
Effect of IBTX on NO-induced relaxation in depolarizing KCl solution. 
Agonist Relaxation (%) 
Nitric oxide (nM) 100 200 400 800 
14.4-20.4 mM KC1 30.0±5.2 50.8±4.6 71.3±3.6 89.6±4.1 
+IBTX 12.0±4.9** 28.3±6.0** 67.8±5.5 92.5±3.3 
35.4-40.4 mMKCl 3.2±2.0++ 13.4db4. I** 41.3±6.90+ 67.4±6.6 
+IBTX 5.3±3.3 17.2±5.2 46.0±4.7 59.1±5.7 
Data are mean ±s.e.m. Number of experiments was six in the low-potassium medium and 
seven in the high-potassium medium. **P<0.01 compared with the corresponding 14.4-
20.4 mMKCl. +P <0.05, ^PO.Ol compared with values obtained in 14.4-20.4 mMKCl. 
Table 1. Effect of IBTX on NO-induced relaxation in depolarizing KC1 solution. 
3.1.2. Effect of NO on the IBTX-sensitive potassium channel in human saphenous vein 
NO in a concentration range of 50-1550 nM dose-dependently relaxed both IBTX 
pretreated and control saphenous vein rings. Significant differences have been found between 
the corresponding values of NO and IBTX+NO (Table 2). In the IBTX pretreated group the 
calculated ECso values of NO was 1471.9 nM and it was 952.7 nM in the control group, 
respectively. 
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Relaxation (%) 
Nitric oxide (nM) 50 150 350 750 1550 
5-HT 1.01.0 5.5±1.2 16.8±4.2 29.9±3.1 65.5±6.9 
5-HT+ IBTX 0.0±0.0 o.o±o.o* 4.5±1.7* 15.4±3.6* 34.8±7.3* 
Table 2. Effect of IBTX on NO-induced relaxation of human saphenous vein. Number of 
preparations=6, Data are mean ± s.e.m., *P<0.05 between the corresponding values of 5-HT 
and 5-HT+IBTX. 
3.2. Investigations of the effect of potassium channel blockers on K v channel 
3.2.1. Effect of 4-AP on human isolated coronary arteries 
The K v inhibitor, 4-AP enhances the basal tone and could induce contraction in the 
human coronary artery in a concentration dependent manner. The contraction amplitude was 
inhibited by a voltage dependent calcium channel inhibitor, NIS (Fig. 4 ). NIS was able to 
reverse, at least in part, the contractile effect of 4-AP. This result proves the potassium 
channel blocking property of 4-AP. Potassium channel block leads to depolarization with 
consequent increase in open probability of voltage dependent calcium channels. 
12.5 nM 125 nM 1.25 pM 12.5 pM 87.5 pM 
50 nM 500nM 5 uM 
2 mill 
37.5uM 187.5 uM 
Nisoldipine 
1 pM 
0.1 pM 
Figure 4. Representative figure, effect of NIS on 4-AP contracted human coronary artery 
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3 '2.2. Effect of 4-AP on the basal tone of canine saphenous veins 
4-AP, in concentrations of 0.0125-5 pM, caused contractions in canine isolated 
saphenous vein preparations in the absence of endothelium In the absence of NA, the 
maximum contractile response was small (1.3±0.57 mN, n=6) and the E C 5 0 value for 4-AP 
was 2.02±0.53 pM. After loading the preparations with 1 mM NA, accumulation of NA in 
noradrenergic nerves of the venous tissues significantly increased the contractions in response 
to repeated administration of 4-AP (Fig. 5.). Under these conditions, the maximum 
contraction of the venous rings increased about eight-fold (10.51±3.64 mN, n=9, p<0.05) 
compared to the non-loaded tissues. The E C 5 0 value was even smaller than in the venous 
preparations without NA filling (0.61±0.3 pM, p<0.05). To detect the role of perivascular 
nerves in the uptake of NA, we destroyed the neuronal vesicles with 6-OHDA (Fig. 5.). After 
this chemical denervation, 4-AP failed to cause contraction up to the largest concentration 
applied (5pM) in canine saphenous vein. 
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Figure 5. Effect of 6-OHDA on the 
contractions induced by 4-AP in 
canine saphenous vein in the absence 
of endothelium. Open circles 
represent the effect of 4-AP. Closed 
circles denote the effect of 4-AP after 
incubation the venous rings with 0.5 
mM 6-OHDA. Number of 
U 
0 
0.01 0.1 1 10 
f 9 f • r • » 
4-AP fuM) 
experiments was seven with and 
without 6-OHDA. */J<0.05 between 
corresponding values of 4-AP and 4-
AP+6-OHDA. Mean values are given 
together with s.e.m. 
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3.3. Investigations of the effect of levosimendan 
3.3.1. Effect of levosimendan in porcine coronary arteries 
3.3.1.1. Effect of GLI on the coronary dilating action of CRO and levosimendan 
CRO and LEVO caused a concentration dependent relaxation on the KC1 
precontracted coronary artery preparations (Fig. 6A and B). 1 pM CRO almost abolished the 
20 mM KCl-induced contraction (93.9±6.9% of the KCl-induced tone, Fig. 6A), an effect 
which was not significantly enhanced further by the increase of the concentration of the drug 
to 5 pM (Emax: 101.5±7.1%). 3.2 pm LEVO completely relaxed the KCl-evoked contraction 
(Fig. 6B). On the basis of the EC50 values, CRO was 4.1-fold more potent (0.10±0.02 pM, 
n=5) than LEVO (0.41±0.10 pM, P<0.01 compared to CRO, n=7) under identical 
experimental conditions in the absence of GLI. 1 pM GLI did not significantly affect the 
contractions induced by KC1 (control: 57.7±7.1 mN and GLI: 63.2±6.9 mN, n=12). This K A T P 
blocking drug decreased the maximum relaxation of CRO (Emax: 47.3±10.7% at 5 pM, Fig. 
6A) while it did not influence the LEVO-induced decrease of coronary tone up to 3.2 pM of 
the inodilator (Emax without GLI: 97.8±8.4%; Emax with GLI: 98.6±10.1%; Fig. 6B). The 
presence of GLI resulted in a 4.6-fold decrease of the potency value for CRO (EC50: 
0.46±0.02 pM, p<0.01 compared to CRO alone, n=5) whereas it did not change significantly 
the potency value calculated for LEVO ( E C 5 0 0.43±0.07 pM, compared to LEVO alone, n=7). 
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Figure 6. Effect of CRO (A) and LEVO (B) on the tone of porcine isolated left descendent 
coronary artery in the absence (o) and presence (•) of 1 pM GLI. Experiments were 
performed in 20 mM potassium chloride-precontracted coronary rings without functional 
endothelium. Magnitude of relaxations was expressed as percent of KCl-induced tone. Data 
represent mean±s.e.m. of 5 (A) and 7 (B) independent experiments. *P<0.05, **P<0.01 
compared with the corresponding values of GLI treated coronary preparations. 
3.3.1.2. Effect of TEA on the coronary dilating action of CRO and levosimendan 
The next series of experiments was aimed at determining the capacity of TEA to 
modify the relaxations induced by CRO and LEVO (Fig. 7A and B). 2 mM TEA pretreatment 
for 5 min did not influence significantly the contractile amplitude of the coronary preparations 
induced by 20mM KC1 (control: 64.4±7.8 mN, TEA: 73.1±7.6 mN, n=6) and caused no 
change in the CRO concentration-response curve (Fig. 7A). Neither the magnitudes of the 
relaxations nor the potency values showed considerable differences in the absence and 
presence of TEA (Emax without TEA: 97.7±9.3%, EC50: 0.16±0.02 pM, n=6; and Emax with 
TEA: 103.6±8.8%, EC50: 0.18±0.03 pM, n=6). 
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The Kca channel blocker did not change the contractile amplitude induced by 20 mM 
KC1 when the effect of LEVO was studied (control: 67.9±5.9 mN, TEA: 64.9±6.2 mN, n=8). 
However, TEA decreased the calculated maximal relaxation of LEVO (Emax without TEA: 
96.6±7.8%, Emax with TEA: 73.8±8.1%, p<0.05, n=8, Fig. 7B). This inhibitory effect was 
evident only at large concentrations of LEVO, i.e. at 1.6 and 3.2 pM of the inodilator drug. 
The EC50 of LEVO did not differ significantly in the absence and presence of TEA (0.24±0.05 
pM and 0.16±0.04 pM, respectively, n=8). 
o = cromakalim - o = levosimendan 
• = cromakalim+ TEA • = levosimendan+ TEA 
0.004 0.01 0.1 1 7 
cromakalim (pM) 
100-1 
0 
0.004 0.01 0.1 1 
levosimendan (pM) 
Figure 7. Effect of CRO (A) and LEVO (B) on the porcine isolated left descendent coronary 
artery in the absence (o) and presence (•) of 2 mM TEA. Experiments were performed in 20 
mM KCl- precontracted coronary rings without functional endothelium. Magnitude of 
relaxations was expressed as percent of KCl-induced tone. Data represent mean±s.e.m. of 6 
(A) and 8 (B) independent experiments. *P< 0.05, compared with the corresponding values of 
TEA treated coronary preparations. 
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3.3.1.3. Effect of IBTX and 4-AP on the coronary artery dilation induced by 
levosimendan 
In third series of experiments another KCa channel blocker, IBTX, and the Kv channel 
blocker, 4-AP, were investigated on the coronary artery relaxing effect evoked by LEVO (Fig. 
8). 100 nM IBTX pretreatment of the coronary preparations for 30 min did not change the 
contractile effect of 20 mM KC1 (control: 75.7±9.9 mN, IBTX: 73.7±6.6 mN, n=8). This KCa 
channel blocker caused a small but significant decrease of the maximal effect of the inodilator 
(Emax without IBTX: 91.7±3.1%, Emax with IBTX: 76.8±4.4%, P<0.01, n=8, Fig. 8A). 
However, the potency of the inodilator was not changed by IBTX (LEVO EC50: 0.48±0.07 
pM, LEVO+IBTX EC50: 0.46±0.04 pM). 10 min incubation of the coronary rings with the Kv 
channel inhibitor, 4-AP (0.5 mM), did not significantly change the contractile sensitivity to 
KC1 (control: 56.9±9.0 mN, 4-AP: 49.8±7.6 mN, n=7), but it decreased the coronary artery 
relaxation induced by LEVO which was significant at as low as 0.5 pM concentration of the 
inodilator drug (Fig. 8B). 4-AP shifted the concentration-response curve for LEVO to the 
right without a change of the maximal relaxation (Emax without 4-AP: 96.4±6.7%, Emax 
with 4-AP: 93.4±8.2%, n=7). The potency of the inodilator was significantly decreased by 4-
AP on the basis of the EC50 values (EC50 without 4-AP: 0.17±0.03 pM, EC50 with 4-AP: 
0.30±0.02 pM, p<0.01, n=7). 
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Figure 8. Effect of LEVO on the coronary artery tone in the absence (o) and presence (•) of 
the calcium-activated potassium channel blocker, 100 nM IBTX (A), or that of the voltage-
dependent potassium channel blocker, 0.5 mM 4-AP (B). Coronary artery rings were 
precontracted with 20 mM KC1. Data represent mean±s.e.m. of 8 (A) and 7 (B) independent 
experiments. *P< 0.05, **P< 0.01 compared with the values obtained with the coronary 
artery preparations in the presence of a potassium channel blocker. 
These experiments were repeated with a larger concentration of 4-AP, as depicted in Figure 9. 
5 mM 4-AP resulted in a small but not significant enhancement of the KCl-induced tone 
(control: 65.7±8.7 mN, 4-AP: 73.1±6.8 mN, n=8), and it decreased considerably the 
maximum relaxing effect of LEVO (Emax without 4-AP: 101.8±6.6%, Emax with 4-AP: 
68.2±6.7%, P<0.01, n=8) with no significant change in the potency value of the inodilator 
drug (EC50 without 4-AP: 0.19±0.03 pM, EC5o with 4-AP: 0.21±0.02 pM, n=8). 
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Figure 9. Effect of 5 111M 4-AP on 
the LEVO-induced porcine coronary 
artery relaxation. Concentration 
response curves represent the effect 
of LEVO on 20 niM KCl-induced 
contraction in the absence (o) and 
presence (•) of the voltage-dependent 
potassium channel blocker. Coronary 
artery rings were precontracted with 
20 mM KC1. Data represent 
mean±s.e.m. of 8 independent 
experiments. *P<0.05, **P<0.01 
compared with the values obtained 
with the coronary artery preparations 
in the presence of 4-AP 
3.3.2. Effect of levosimendan on human internal mammary artery 
1 pM NA dose dependently contracted the isolated internal mammary artery (IMA) 
rings and the effect did not change significantly at various prestretched values (4.34±2.32 mN 
at 23 mmHg, 3.32±1.46 mN at 46 mmHg and 4.85±1.43 mN at 92 mmHg, n=16, ns). This 
suggests that there is no difference between the spasm reactions caused by sympathetic 
activity, in vitro. LEVO caused significantly higher relaxation at lower tones than at 92 
mmHg. The vasorelaxing effect showed decreased tendency at increased pressure (0.6pM 
LEVO: -80±15.3% at 23 mmHg, -65.8±12.1% at 46 mmHg, -32.0±8.1% at 92 mmHg, n=8, 
P<0.05 23 vs 46 mmHg, Fig 10.). 
Figure 10. Effect of LEVO on Na-
precontracted isolated human IMA 
at various simulated transmural 
pressure (23, 46, 92 mmHg). 
Values mean increase (+) and 
decrease (-) of the tone, where 
100% is the maximum amplitude of 
NA contraction. IMA rings were 
precontracted with 1 pM NA. Data 
represent mean ± s.e.m. of 8 
independent experiments. P< 0.05, 
*P<0.05 compared with the similar 
concentration of LEVO obtained 
with the 23 and 46 mmHg pressure 
prestretching. 
3.3.3. Effect of levosimendan in canine saphenous vein 
Two different levels of calculated venous pressure (10 and 20 mmHg) were simulated 
in two parallel in vitro baths, separately. After NA induced contraction, LEVO caused a 
concentration dependent decrease of venous tone both at 10 and 20 mmHg (Fig. 11.). When 
basal tone was set at 20 mmHg, LEVO exerted significantly higher relaxations than at 10 
mmHg. 3.4 pM LEVO caused 73.6±1.0% decrease of NA induced tone at 10 mmHg, (Fig. 
11.). The venodilating effect was diminished by 1.5 pM GLI to 54.0±2.5%, p<0.01. At 10 
mmHg venous pressure the 50% effective concentration ( E C 5 0 ) of LEVO was calculated to be 
0.75 pM in the presence of the drug alone and 1.1 pM in combination with GLI. In the 
simulated high intraluminal pressure group LEVO exerted a maximum of 91.4±1.0% decrease 
of NA-induced tone which decreased to 57.4±2.3% in the presence of GLI ( E C 5 0 : 0.96 pM 
LEVO alone and 1.26 pM LEVO+GLI, Fig. 13.). 
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Figure 11. Effect of LEVO at 
enhanced levels of basal tone in 
canine saphenous vein. 
Concentration response curves 
represent the effect of LEVO at 
various prestretched tone. Venous 
rings were precontracted with 3.25 
pM NA. Data represent mean±s.e.m. 
of 5 independent experiments. 
*P<0.05 compared with the similar 
concentration of LEVO obtained with 
the 10 and 20 mmHg pressure 
prestretching. 
Figure 12. Effect of 1.5 pM GLI on 
LEVO-induced venodilation at 10 
mmHg in canine saphenous vein. 
Concentration response curves 
represent the effect of LEVO at 10 
mmHg basal tone in the presence (o) 
and absence (•) of 1.5pM GLI in NA 
precontracted (3.25 pM) veins. 
Magnitude of relaxations was 
expressed as percent of NA-induced 
tone. Data represent mean±s.e.m. of 5 
independent experiments. *P<0.05, 
**P<0.01 compared with the 
corresponding values of GLI treated 
saphenous vein preparations. 
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Figure 13. Effect of 1.5 pM GLI on 
LEVO-induced venodilation at 20 
mmHg in canine saphenous vein. 
Concentration response curves 
represent the effect of LEVO at 20 
mmHg basal tone in the presence 
(o) and absence (•) of 1.5pM GLI 
in NA precontracted (3.25 pM) 
veins. Magnitude of relaxations was 
expressed as percent of NA-induced 
tone. Data represent mean±s.e.m. of 
5 independent experiments. 
*P<0.05, **P<0.01 compared with 
the corresponding values of GLI 
treated saphenous vein 
preparations. 
It can be seen that the GLI-sensitive component of LEVO-induced relaxation 
remained virtually the same at the two different levels of calculated venous tone. In all of our 
venous preparations E C 5 0 of LEVO was below 1 pM. 
3.3.4. Effect of LEVO in human portal vein 
3.3.4.1. Effect of CRO and LEVO on the tone of human isolated portal vein 
Both CRO and LEVO relaxed the NA-precontracted portal vein preparations almost 
completely (Fig. 14.). 
Typical concentration-response registration were derived from one out of seven 
independent experiments in the case of both CRO and LEVO (Fig. 14A and B, respectively). 
On the basis of the EC50 values, LEVO was 16.1-fold more potent (EC50: 0.281±0.03 pM, 
n=7) than CRO (EC50: 4.53±0.12 pM, n=7) under identical experimental conditions. 
Levosimendan (pM) 
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Figure 14. Typical concentration-
response tracings for the relaxations 
induced by CRO (A) and LEVO (B) in 
human isolated portal vein. Contractions 
of venous rings were induced by 10 pM 
NA (upward arrows). Downward arrows 
represent the addition of cumulative 
concentrations of CRO (dotted line A: 
0.2, 0.9, 2.5, 5.7, 12.0, 24.2 and 47.2 pM, 
respectively) and LEVO (dotted line B: 
0.01, 0.03, 0.07, 0.15, 0.31, 0.63 and 1.3 
pM, respectively) or the corresponding 
volumes of solvent (solid lines A and B). 
The original registrations are 
representatives of 7 independent 
experiments for each curve. 
3.3.4.2. Effect of GLI on the venodilating action of CRO and levosimendan 
Another series of experiments was aimed at determining the capacity of GLI to modify 
the relaxations induced by CRO and LEVO (Fig. 15.). Pretreatment of the portal vein 
preparations with 1.5 pM GLI for 30 min caused a significant leftward shift in the CRO 
concentration-response curve, but had no effect on the maximum relaxation response (Fig. 
15A.) However, a ten-times-higher GLI concentration (15 pM) inhibited the relaxation by 
CRO (up to 48 pM) almost completely (Fig. 15 A.). A low concentration of GLI (1.5 pM) also 
decreased LEVO-induced relaxation, the maximum amplitude of the relaxation was also 
depressed (Fig. 15B.). A high concentration of GLI (15 pM) further decreased the effect of 
LEVO, but this effect did not differ significantly from that produced by the low GLI 
concentration (Fig. 15B.). 
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Figure 15. Effect of 1.5 pM • and 
15 pM • GLI on the relaxations 
induced by CRO (A, • ) and LEVO 
(B, •) in NA-precontracted human 
portal vein. Magnitude of 
contractions was expressed as 
percent of NA-induced tone. Data 
represent mean values ±s.e.m. of 7 
independent experiments in the case 
of CRO and 6 in the case of LEVO. 
*P< 0.05, **P< 0.01, ***P< 0.001 
compared with CRO or LEVO 
alone; f t P< 0.01, f f f P< 0.001 
compared with 1.5 pM GLI 
treatment. 
3.3.4.3. Effect of GLI on the basal tone and on the NA-induced contraction 
The basal tone, which was set up to 40 mN (about 4g), remained unchanged during the 
entire equilibration period (45 min). Even the large concentration of GLI (15 pM) applied did 
not influence this tone until the end of the 30 min incubation period (change in basal tone: 
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0.13±0.01 mN, n=7). Similarly, NA-induced contractions were not significantly affected by 
15 gM GLI (17.3±1.6 mN vs 17.4±2.6 mN in the presence and absence of GLI, respectively, 
n=7). 
3.3.5. Effect of levosimendan in human saphenous vein 
3.3.5.1. Effect of GLI on the venodilating action of levosimendan 
Relaxation by LEVO was studied in the presence and absence of GLI (Fig. 16A.). In 6 
independent experiments, 30 min preincubation of the saphenous rings with GLI did not 
significantly influence the maximum amplitude of the 5-HT-induced tone (control: 
+12.70±6.36 mN vs GLI: +9.24±5.18 mN). LEVO produced a maximum of 28.1±7.5% 
relaxation with an EC5o of 0.32±0.04 pM. GLI abolished the relaxing effect of 0.13 and 0.31 
pM concentrations of LEVO with a 40 times increase of the E C 5 0 of the inodilator drug 
(12.8±0.8 pM). 
Figure 16. Effect of GLI and IBTX on LEVO-induced relaxation of human isolated 
saphenous vein. Part A: Effect of LEVO in the absence (•) and presence (•) of 15 pM GLI. 
Part B: effect of LEVO in the absence (•) and presence ( • ) of 90 nM IBTX. Values are 
expressed as percentage of the steady-state contraction induced by 5-HT and represent means 
±s.e.m. of 6 experiments. Statistically significant difference from the effect of LEVO in the 
absence of GLI or IBTX: *P< 0.05, **P< 0.01. 
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3.3.5.2. Effect of IBTX on the venodilating action of levosimendan 
In a separate series of 6 experiments, the effect of LEVO was investigated in IBTX-
pretreated saphenous rings (Fig. 16B.). 30 min preincubation of the preparations with IBTX 
did not influence the 5-HT-induced tone (control: +24.73+17.11 mN vs IBTX: +20.53+10.42 
mN). In these experiments, the maximum relaxation induced by LEVO was 36.5+14.9% with 
an EC50 of 0.25+0.03 pM. In the presence of IBTX, LEVO induced concentration-dependent 
contraction of the veins which became significant at and above 0.31 pM. For this effect the 
EC50 of the drug amounted to 0.21+0.06 pM. 
'•T 
4. DISCUSSION 
4.1. Investigations on BKca channel 
4.1.1. Role of BKca channels in the vasodilating mechanism of NO in canine coronary artery 
Nitric oxide is released from the vascular endothelium of blood vessels and functions 
as a coronary artery autoregulator. The effector signalling of NO is known to be cyclic GMP 
in the smooth muscle cells that decreases the tone of arteries and veins. However, a 
hyperpolarizing mechanism of NO on the arterial smooth muscle membrane has also been 
suggested (Tare et al 1990). The sensitivity of vasorelaxation to the known hyperpolarizing 
potassium channel activator, CRO, and to NO as well as that of the specific antagonists of 
potassium channels, K A T P and BKCA, revealed that NO is a potassium channel activator in 
canine conduit type of coronary arteries. The results also show that the KATP and BKCA ion 
channels are functionally distinct entities. 
In canine coronary vessels, the KATP blocker, GLI inhibited the relaxation response to 
CRO, while IBTX, the known most selective BKca blocker (Garcia et al 1991), decreased the 
relaxing effect of NO. Furthermore, the relaxation by CRO was not affected by IBTX at all 
and CRO is known to have no influence on cyclic nucleotides (Taylor et al 1988). A large 
density of BKca channel was measured in the isolated smooth muscle cells of canine coronary 
arteries (Wilde & Lee 1989; Taniguchi et al 1993) and NO has been found to open BKca 
channels in rabbit aorta (Bolotina et al 1994). These findings strongly support a functional 
connection between the endothelial mediator, NO and the effector BKca channel at the level 
of the smooth muscle cells. In our experiments, the effect of 100 and 200 nM but not 400 and 
800 nM NO was decreased by IBTX in a medium of low potassium (<20.4 mM KC1). 
Elevation of potassium concentration to 35.4-40.4 mM significantly depressed the relaxation 
by NO, and under this condition the IBTX-sensitive component disappeared. These results 
point to the important role of the membrane potential in the vasorelaxing mechanism of NO 
similar to the original observation in rat uterine artery (Tare et al 1990). Taken together all 
these findings we suggest that BKca channel is also an effector signal and mediates, at least in 
part, the coronary autoregulatory function of the endothelial NO. 
It is important to note that limited observations are available for a functionally distinct 
BKca channel in the circulatory tree. In conscious dogs coronary dilating mechanisms by 
another KATP opener, pinacidil, and by sodium nitroprusside, a cGMP-elevating drug, can be 
separated by pharmacological means (Duncker et al 1993). However, using other blood 
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vessels, some observations support (Strong et al 1989; Green et al 1991), while others 
contradict (Gelband et al 1989; Okabe et al 1990) the findings in coronary arteries raising the 
possibility that the functions of K A T P and B K C A channels can not be separated in some blood 
vessels. One possible explanation is that the prototype K A T P opener, CRO, also relaxes 
smooth muscles through activation of BKca channels, indicating a non-specific potassium 
channel activating characteristics of this group of drugs (Balwierczak et al 1995). 
Further evidences for functionally distinct potassium channels were obtained 
regarding the basal tone of canine isolated coronary arteries. Basal tone in our in vitro organ 
bath is represented by a passive stretch (10-40 mN) applied on a vascular ring perpendicular 
to the vessel wall. The basal tone was not affected by GLI but was increased by IBTX 
supporting a previous assumption that BKca channels regulate the basal tension in epicardial 
coronary arteries of the dog, at least under in vitro conditions (Taniguchi et al 1993). 
Although K A T P channels were also suggested to be an important metabolic autoregulator in 
canine coronary blood vessels at rest, this type of potassium channels appears to be localized 
in the smooth muscle of resistance coronary arteries (Ishibashi et al 1998). 
Our present experimental results may have therapeutic relevance. NO is an active 
metabolite of nitroglycerine (NTG) and is released enzimatically from NTG in coronary 
arteries (Chung & Fung 1993). NTG increases cyclic guanosine 3,5-monophosphate (cGMP) 
in the smooth-muscle cell which is associated with relaxation (Ignarro & Kadowitz 1985). In 
isolated canine coronary arteries, the open probability of BKca channels was increased by 
NTG, 8-bromo-cGMP (Fujino et al 1991) as well as by cGMP-dependent protein-kinase 
(Taniguchi et al 1993) suggesting the regulation of BKca channels by the cGMP-messenger 
system. A functional effect of NTG, as a major coronary dilator, on BKca channels has been 
demonstrated (Pataricza et al 1995). These findings are in agreement with the observation that 
1 pM NTG decreased the amplitude of the action potential evoked by TEA (Harder et al 
1979), a nonselective inhibitor of Kca channels (Nelson et al 1990). 
In conclusion, there are at least two potassium channels, K A T P and BKca, that can be 
activated or inhibited in epicardial coronary arteries of dogs. We have demonstrated that 
exogenous NO has an IBTX-sensitive mechanism in its acute coronary artery vasodilator 
action in vitro. 
4.1.2. Role of BKca channels in the vasodilating mechanism of NO in human saphenous vein 
NO caused dose-dependent relaxation in the IBTX pretreated and control saphenous 
vein rings and the relaxation was significantly smaller in the IBTX pretreated group. We have 
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demonstrated, for the first time, that BKca channels regulate the tone of human saphenous 
vein. In the light of the above finding we suggest that the known decreasing effect of NTG in 
preload in vivo may also be due to NO-induced opening of BKca channels (Hohn et al 1995), 
a mechanism that is suggested to be functional in the epicardial coronary artery of the dog 
(Pataricza et al 1995). 
In conclusion, NO has a vasodilator mechanism that differs from the known increase 
of cGMP in the smooth muscle cells both in the conduit coronary arteries and in the 
capacitive vein. This mechanism involves BKca channel mediating a part of the relaxing 
effect of NO. We suppose that NO indirectly opposes the calcium entry into the smooth 
muscles of the coronary artery and saphenous vein through hyperpolarization of the cell 
mebrane. In a pharmacological point of view NO-donor drugs, such as NTG, may protect the 
coronary arterial and venous smooth muscle against depolarization-induced calcium overload 
(Brayden & Nelson 1992). 
4.2. Investigations on Kv channel 
4.2.1. Regulatory role of Kv channel in a human isolated coronary artery 
4-AP, the known Kv channel blocking reference substance, concentration dependently 
enhanced the basal tone of a human coronary arterial ring. NTS, a blocker of L-type voltage-
dependent potassium channels (L-VOCCs), partially reversed the 4-AP induced increase of 
the coronary arterial tone. This phenomenon corresponds to the hypothesis that depolarization 
enhances the open probability of L-VOCCs (Brayden & Nelson 1992) and the increase of 
calcium entry through the cell membrane is the mechanism by which 4-AP causes contraction 
in conduit coronary arteries. 
4.2.2. Regulatory role of Kv channel on the basal tone of canine saphenous veins 
Release of NA from the sympathetic nerve terminals has been shown to be regulated 
by Kv channels (Takata et al 1992). Venus blood vessels are richly innervated with 
sympathetic nerves, and potassium channels of Kv type appear to be present in some veins 
(Kato and Takata 1987; Hara et al 1980). In our experiments the Kv channel blocker, 4-AP 
was able to enhance the basal tone of isolated canine saphenous vein in a submicromolar 
concentration range, in vitro. The calculated EC50 value of the drug was 0.61 pM in the 
endothelium denuded venous rings only when the venous neuronal stores were filled with 
NA. This potency value is in the same magnitude of 4-AP concentrations measured in plasma 
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of patients suffering from spinal cord injury (27.7 ng/ml, i.e., 0.3 pM; Segal et al 2000) and 
almost the same as the serum level measured in multiple sclerosis (0.65 pM, Van Diemen et 
al 1993). 0.6-5 pM 4-AP was able to release NA from frog sympathetic ganglion (Kumamoto 
& Kuba 1985). 
Chemical denervation by 6-hydroxydopamine (6-OHDA) of our saphenous 
preparations after filling (loading) the NA store of the venous tissue was performed in vitro. 
The hyperpolarizing potassium channels supposedly have an important role in the regulation 
of transmitter release, which was proved in animals of lower species (Kumamoto & Kuba 
1985). Szentivânyi et al proved the contractile effect of 4-AP on human capacitive vessels, 
but there was no evidence for the mechanism (Szentivânyi et al 1997). The chemical damage 
with 6-OHDA of the sympathetic nerve terminals is an accepted method in vitro and also in 
vivo experiments (Huang et al 1995; Villanueva et al 1994; Medhurst et al 1993). 4-AP 
inhibited the voltage-dependent potassium channel, in milimolar concentration in smooth 
muscle cell investigations (Halliday et al 1995). However, in our studies 4-AP enhanced the 
basal tone in micromolar concentration, at least after filling the neuronal store with NA and 
this effect was completely inhibited with 6-OHDA. This finding supports an indirect neuronal 
mediation of the effect of low concentrations of 4-AP on venous tone. 
Our conclusion is that the activity of Kv -type potassium channels largely determines 
the tone of capacitance saphenous vein through controlling the release of the sympathetic 
neurotransmitter, NA. Although epicardial coronary arteries also have autonomic innervation 
we did not measure the possible role of Kv channels in arterial neurotransmission. In porcine 
coronary artery, a work from Kun et al demonstrated that the contractile effect of 4-AP is 
partially mediated by neuronal 5-HT (Kun et al 2000). Therefore, in both capacitance veins 
and partly in conduit arteries, neuronal Kv channels regulate the vascular tension and this 
mechanism may be relevant for in vivo conditions when the sympathetic tone is elevated. 
4.3. Investigations on the effect of the inodilator, levosimendan 
4.3.1. Role of KATP, Kca and Kv types of potassium channels in the coronary artery dilating 
action of CRO and levosimendan in porcine coronary arteries 
LEVO is an inodilator drug used to treat heart failure. In 1997, Yokoshiki et al 
demonstrated that the vasodilating action of LEVO is mediated through hyperpolarization of 
the smooth muscle membrane of isolated mesenteric arterial myocytes (Yokoshiki et al 
1997a). The authors suggested that the hyperpolarizing effect was due to opening of K A T P 
channels by the inodilator drug. The KATP channel has also been proposed to be a target for 
LEVO in small coronary arteries of the dog (Kersten et al 2000) and in the human portal vein 
(Pataricza et al 2000). Our investigations indicate the activation of two other hyperpolarizing 
potassium channels, Kca and Kv, by LEVO in the epicardial coronary artery preparations 
isolated from the porcine heart. In our studies, four inhibitors of potassium channels were 
used to characterize the mechanism of LEVO-induced coronary artery relaxation. 
The interaction between CRO and GLI revealed the presence of functional K A T P 
channels in our isolated porcine coronary artery preparations. The same concentration of GLI, 
however, was without any effect on the relaxation induced by LEVO. The opposite results 
were obtained with 2 mM TEA a non-specific blocker of Kca channels: TEA had no effect on 
CRO whereas it decreased the maximum effect of LEVO. This finding strongly supports the 
role of different subtypes of potassium channels in the vasorelaxing mechanisms of CRO and 
LEVO. IBTX, the BKca blocker, caused a small but not significant decrease in the maximum 
effect of LEVO suggesting the involvement of the large-conductance subtype of Kca channels 
in the vasodilating mechanism. The effect of the inodilator was also significantly decreased 
by 0.5 mM 4-AP, a potent inhibitor of the Kv channels in this type of blood vessels (Shimizu 
et al 2000). Interaction with 4-AP was evident even at as low as 0.05 pM concentration of the 
inodilator drug. Thus, the low submicromolar concentrations of LEVO seem to activate Kv 
channels, while the drug, in larger concentrations, activates both Kv and Kca channels in 
porcine epicardial coronary artery. Ten-fold larger concentration of 4-AP (5 mM) decreased 
the maximum effect of LEVO by 43%. However, this concentration of 4-AP is non-specific 
and has also been shown to affect the BKca channels in this artery (Fujino et al 1991; 
Petkova-Kirova et al 2000). Therefore, the functional effect of two potassium channels, the 
Kv and Kca channels, are presented as targets for the effect of the inodilator, LEVO, in the 
porcine coronary artery. 
One might argue for the lack of effect of the LEVO on the KATP channels, a known 
target for the drug in other vascular tissues (Yokoshiki et al 1997a; Pataricza et al 2000; 
Kersten et al 2000). The functional importance of this type of potassium channels is evident in 
the present investigation. It is important to note that some pharmacological and 
electrophysiological properties of K A T P channels in porcine coronary artery have been 
suggested to differ from those of other blood vessels (Inoue et al 1989; Wakatsuki et al 1992). 
The non-specific potassium channel activating property of LEVO observed in the present 
experiments is also supported by the agonist activity of the drug on mitochondrial KATP 
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channel (Kopustinskiene et al 2001) which is pharmacologically different from those KATP 
channels located in the cell membranes. 
LEVO is an approved drug under the trade name of Simdax for treating severe heart 
failure (Papp et al 1999). Another important finding of the present work is that the drug-
induced decrease of the large epicardial coronary tone could be achieved at therapeutically 
meaningful concentrations (Sandell et al 1995). This effect of the inodilator may also be 
relevant to the human coronary arteries in vivo (Krassoi et al 2000). Furthermore, the 
interaction of LEVO with 4-AP might have clinical significance because 4-AP is a therapeutic 
tool in some neurologic disorders (fampridine). 
In the light of the present findings we conclude that LEVO effectively and directly 
decreases the tone of the epicardial coronary artery preparations isolated from the porcine 
heart. This effect may induce coronary dilation in vivo in those submicromolar concentrations 
of the drug which were proved to exhibit inotropic effect on the heart (Haikala & Linden 
1995). It appears that the mechanism of vasodilating action of LEVO depends, at least in part, 
on potassium channels functionally differing from the KATP channels. 
It is important to mention that a species difference exists concerning the regulation of 
the basal coronary artery tone by BKca channels. Under in vitro conditions, canine but not 
porcine coronary artery showed an elevation of the resting tone after administration of IBTX. 
While Kv channels appear to have regulatory role in the basal tone of human coronary artery, 
evidence for the role of BKca channels is lacking at present. 
4.3.2. Vasodilation by levosimendan in relation to simulated transmural pressure in human 
internal mammary artery 
During bypass surgery hypoxia, low temperature and low perfusion pressure can 
provoke spasm of bypass conduits including IMA. We simulated different perfusion pressures 
in isolated IMA rings obtained from coronary artery bypass surgery. Passive stretches were 
applied perpendicular to the wall of IMA under in vitro conditions and calculated as 23, 46 
and 92 mmHg transmural pressures according to the Laplace law. 
NA-induced contractile responses did not differ at the three simulated values of 
pressure suggesting that the elevated sympathetic tone alone might contribute to contraction 
independently of the actual transmural pressure of the IMA graft. 
Myogenic tone of the blood vessels is activated when the transmural pressure is high 
according to the Starling law. The vasodilating effect of 0.3 and 0.6 pM LEVO decreased 
with increasing pressure of IMA, indicating that depolarization associated with enhanced 
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myogenic tone counteracts the effect of a hyperpolarizing vasodilator. Although we did not 
present evidences that LEVO hyperpolarized the smooth muscle of this conduit graft, the 
inodilator drug was shown to activate KATP channels in isolated IMA samples (Yildiz et al, 
personal communication). Under identical conditions, nifedipine exerted maximum 
vasodilation at a medium level of pressure (46 mmHg) supporting the maximum activation of 
calcium channels at higher transmural pressure and consequently more depolarized state of 
IMA in comparison to the activation of potassium channels (Hegediis et al 2002). 
In conclusion LEVO is an effective dilator of isolated IMA in submicromolar 
concentrations and may have important therapeutic value especially at low perfusion of the 
graft in the perioperative setting. 
The limitation of the above method is that the Laplace law serves only approximate 
pressure values because the equation can be applied for those small blood vessels in that the 
wall thickness/diameter ratio is smaller than about 1/100. 
4.3.3. Vasodilating effect of LEVO at different levels of simulated pressure in canine 
saphenous vein 
Veins from the saphenous region are used extensively to test vasodilator substances 
because they are highly selective to the effects of cardiovascular factors (Hollander et al 
1976). Canine saphenous veins were found to possess KATP channels (Nakashima & 
Vanhoutte 1994) and responded with changes in tone to the effect of different potassium 
channel activators and inhibitors. In this section of the work, submicromolar concentrations of 
LEVO have shown to exert similar effectiveness at moderate (10 mmHg) and high (20 
mmHg) venous tones simulated by the enhancement of perpendicular wall stretch under in 
vitro conditions. 1.5 pM GLI significantly inhibited LEVO-induced relaxations even in the 
submicromolar concentration range of the inodilator drug. This was evident at the two 
different values of pressure. These results are in accordance with our observations obtained in 
saphenous and human portal vein (Pataricza et al 1998). In the present study, we did not use 
higher concentrations of the KATP channel inhibitor, GLI, because of its known non-specific 
action on other ion channels (e.g. chloride channel). 1.5 pM GLI represents a therapeutic 
concentration of the antidiabetic compound that can cause a decrease but not complete 
inhibition of LEVO-induced venodilation. The sensitivity of the effect of LEVO to inhibition 
by GLI is known from other studies including arterial myocytes (Yokoshiki et al 1997a) and 
cardiac ventricular cells (Yokoshiki et al 1997b). However, it appears that the venous smooth 
muscle is the most sensitive type of vascular tissues with respect to the activation of KATP 
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channels by LEVO. This mechanism may play a role in the therapeutic effect during 
administration of the drug to patients suffering from congestive heart failure. 
In conclusion, LEVO is an effective venodilator at two simulated venous pressures. 
The inodilator appears to be effective at higher transmural pressure, an effect that may 
decrease pathologically elevated preload in heart failure. Under these conditions, LEVO 
retains its sensitivity to GLI and interaction of the two drugs may have important therapeutic 
consequences. 
4 . 3 . 4 . Role of K A T P channel in the vasodilating effect of L E V O in human portal vein 
The KATP channel activator, CRO relaxed the NA-contracted human isolated portal 
vein. LEVO, which was shown to increase the open probability of K A T P channels in isolated 
arterial myocytes (Yokoshiki et al 1997a), was also found to be effective and to be a more 
potent relaxant than CRO in human portal venous preparations. GLI, a K A T P channel blocker, 
inhibited the CRO-induced relaxation of the portal vein, while it partially decreased the effect 
of LEVO. GLI did not change the basal tone of portal veins and also did not significantly 
affect the contractions induced by NA. This finding supports the specificity of interactions 
between GLI and CRO or LEVO. However, it is worth mentioning, that the 15 pM GLI-
sensitive component of the LEVO action might also be related to mechanisms other than 
opening K A T P ion channels (Tominaga et al 1995). 
An increase in sympathetic nervous activity has been recognized in cirrhosis and heart 
failure associated with portal hypertension or congestion. Portal vasoconstriction to NA was 
shown to be enhanced in experimental cirrhosis (Mathie et al 1996). In this part of our work, 
both CRO and LEVO antagonized the contractile effect of NA in the portal vein, although 
neither of the drugs have adrenergic-receptor-blocking activities (Harkin et al 1995). The 
possible significance of administering CRO and LEVO in portal hypertension would produce 
a selective effect on the portal circulation as compared with the effect of these drugs on the 
splanchnic arterial bed. We have no functional evidence for this assumption, but the low 
potency of LEVO for opening K A T P channels in mesenteric arterial myocytes (ECso= 2.9 pM; 
Yokoshiki et al 1997c) strongly suggests this possibility. Furthermore, it has been 
demonstrated that the tone of NA-contracted portal vasculature was sensitive to GLI (Mathie 
et al 1996), while the splanchnic circulation was not affected (Ralevic et al 1996). Our present 
experimental observations point to the role of a CRO-type vasodilator mechanism in the 
human portal vein which could be activated by drugs involving GLI-sensitive potassium 
channels. 
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The inodilator drug, LEVO, has been shown previously to decrease the preload of the 
heart in intact conscious dogs (Harkin et al 1995) and in dogs with failing heart (Udvary et al 
1995). The maximum inotropic effect of LEVO was attained at submicromolar concentrations 
(0.2 pM; Sandell et al 1995; 0.3 pM, Haikala et al 1997), corresponding to the effective 
concentrations of the drug in human portal vein. 
In conclusion LEVO might be beneficial as an adjuvant drug for treating portal 
hypertension. 
4.3.5. Role of KATP and BKCa channels in the vasodilating effect of levosimendan 
in human saphenous vein 
In this part of our work, LEVO was found to decrease the 5-HT-induced tone of 
human isolated saphenous vein. The drug caused venodilation in concentrations which are 
attained in the clinical therapy of heart failure. Our finding supports a previous assumption 
that the LEVO-induced diminution of cardiac preload is due to a direct action of the drug on 
the venous tone (Harkin et al 1995; Udvary et al 1995). The action in the human portal vein 
(chapter 4.3.4.) and in human saphenous vein suggest a receptor independent vasodilation 
induced by the drug as it was also found in isolated porcine coronary artery (Gruhn et al 
1998). 
Venodilating effect of LEVO was partially inhibited by GLI, reflecting some role of 
the hyperpolarizing ATP-sensitive potassium channels (KATP) in the mechanism of action of 
the drug. The Kca channel appears to be important in regulation of the saphenous tone (Hohn 
et al 1995). Therefore, the involvement of this type of potassium channels was plausible 
(Pataricza et al 2003). Furthermore, the BKca channel revealed cation activation 
characteristics similar to troponin C (Lattore et al 1989), the latter being absent in smooth 
muscles, but comprising the primary target site for LEVO in the heart (Haikala et al 1995). In 
the present study IBTX, a selective inhibitor of BKca channels, interacted with the 
venodilating effect of LEVO. This type of interaction unmasked concentration-dependent 
contractile effect and was without a change in the EC50 value of the inodilator (Hohn et al. 
2004). This suggests the presence of different binding sites for LEVO and IBTX in the 
saphenous vein. The exact mechanism involved is, however, speculative for the time being. 
Nevertheless, such interaction at submicromolar concentrations of LEVO may offer a future 
therapeutic consequence of our finding. 
The BKca channel is a "blood vessel-specific" potassium channel which, according to 
our current knowledge, has no functional role in the heart. Thus, we suppose that any 
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pharmacological modulation of BKca channels, which is a developing field in vascular 
research, interferes only with the vasodilating but not with the inotropic effect of LEVO 
(Pataricza et al 2003, Yokoshiki & Sperelakis 2003). 
In conclusion, we have provided evidence for a so far unknown effect of LEVO in a 
human capacitance blood vessel, an interaction with a hyperpolarizing BKca channel blocker. 
In addition to its known K A T P channel activating property, a presumed effect of the inodilator 
drug on the BKca channel might contribute to the decrease in cardiac preload. The 
consequence would be a beneficial haemodynamic effect complementing the inotropic action 
of LEVO in the treatment of severe heart failure. 
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